Barclays lowered the firm’s price target on Orchestra BioMed (OBIO) to $12 from $16 and keeps an Overweight rating on the shares. The firm increased its loss estimates through 2027 to reflect the company’s increased research and development spend over the next three years, with easing spending in the subsequent three years. The analyst cites lower group multiples, rather than concerns in the underlying business, for the target cut.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OBIO:
- Orchestra BioMed Receives FDA Approval for IDE Amendment
- Orchestra BioMed receives approval of IDE to initiate Virtue Trial
- Orchestra BioMed Holdings: Buy Rating Affirmed on Breakthrough Device Designation and Promising AVIM Therapy Developments
- Orchestra BioMed granted breakthrough device designation, says H.C. Wainwright
- Orchestra BioMed announces AVIM therapy-focused satellite symposium at HRS 2025